The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients.
Three topics are discussed. Enhanced anti-tumor efficacy of targeted doxorubicin-containing sterically-stabilized liposomes using an anti-beta1 integrin Fab' ligand. Use of tumor targeting with an internalizing ligand to improve the efficacy of a non-leaky cisplatin-containing sterically-stabilized liposome formulation. Formulation variables (remote-loading with dextran ammonium sulfate, rigid lipid bilayer) used to optimize in vivo performance of a liposomal camptothecin analog.
Abra
R M
RM
ALZA Corp, Mountain View, California 94025, USA.
Bankert
R B
RB
Chen
F
F
Egilmez
N K
NK
Huang
K
K
Saville
R
R
Slater
J L
JL
Sugano
M
M
Yokota
S J
SJ
D000645:Ammonium Sulfate / Q000494:pharmacology; D000925:Anticoagulants / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003911:Dextrans / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage; D016503:Drug Delivery Systems; D008024:Ligands; D008051:Lipid Bilayers / Q000378:metabolism; D008081:Liposomes / Q000378:metabolism*
D000925:Anticoagulants; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D003911:Dextrans; D008024:Ligands; D008051:Lipid Bilayers; D008081:Liposomes; D004317:Doxorubicin; D002945:Cisplatin; D000645:Ammonium Sulfate; D002166:Camptothecin